Rose Maciewicz

  • Chief Scientist  in the Respiratory, Inflammation, Autoimmunity iMed at AstraZeneca, Cambridge, UK
  • Honorary Professor University of Manchester and University of Glasgow

Rose Maciewicz studied at the University of Buffalo graduating with a BA in Biology (Summa Cum Laude) in 1976, and a MA (1978) followed by a PhD (1980) in Cell and Molecular Biology.  Upon completing her PhD, on in vivo hormonal induced gene activation, she undertook a Post Doctoral Research Associate position at The Johns Hopkins University, Department of Biology, Baltimore,  Maryland where she investigated the structure-function relationship of gene activation at the nucleosomal level.  Moving to the UK she did further postdoctoral work on cysteine and metalloproteinases in disease which was funded by the Arthritis Research Council as well as collaborated on projects funded by the Cancer Research UK.  She undertook a sabbatical as a group leader at a biotech company (Prototek) in California before she joined AstraZeneca (legacy companies ICI, Zeneca).  At AstraZeneca she has held various leadership positions in science, project as well as management.   She has in-depth experience in research and early development across a broad range of diseases including musculo-skeletal, cardiovascular and respiratory diseases.   Projects she initiated in the osteoarthritis area are currently in clinical development.  Externally she has been a committee members for various taskforces / steering groups that have set the future agenda in osteoarthritis, as well as private public partnerships in regenerative medicine (Regener8) and stem cells in drug discovery (SC4SM).  She has been an external advisor for orthopeadic companies.  A previous committee member and Secretary of the British Society for Matrix Biology, she currently sits on the Scientific Advisory Board for Arthritis UK Pain Centre, the Board of Directors for the Manchester Collaborative Centre for Inflammation Research (MCCIR) and the White Rose University Centre doctoral training program funded by the BBSRC.  She has established and for 5 years lead a highly-regarded internal postdoctoral programme in AstraZeneca that currently supports over 120 post-docs. She has organised major external conferences.  She collaborates widely with the external academic community and has published extensively.  Current research interest include long non-coding RNA and post translational protein modifications as points of molecular regulation of cellular event and drug exploitation.